Sabuwar Alamar Jafananci akan Alurar Ciwon Ovarian

“Mun yi farin cikin sanar da wannan ƙarin kariyar kariyar mallakar fasaha ta novel Anixa's novel cancer cancer, wadda aka samar a Cleveland Clinic kuma ana nazari a NCI. Wannan fasaha ta musamman tana da yuwuwar zama rigakafin farko don hana ciwon daji na ovarian, wanda ya kasance ɗayan mafi muni da wahala don magance cutar kansa, ”in ji Dokta Amit Kumar, Shugaba, Shugaba da Shugaban Anixa Biosciences. "Idan an yi nasara, wannan maganin zai iya hana ciwon daji na ovarian daga faruwa kuma ya hana marasa lafiya yin maganin chemotherapy da manyan jiyya, kuma yana iya ceton rayuka. Muna sa ran ci gaba da aikinmu na yau da kullun da fatan cewa wannan rigakafin za ta ƙara wa arsenal ɗin da ake buƙata don magance wannan ƙalubalen ciwon daji kuma a ƙarshe ya kawo canji ga yawancin marasa lafiya. "

Maganin ciwon daji na ovarian yana hari akan yanki na waje na anti-Müllerian hormone receptor 2 (AMHR2-ED), wanda aka bayyana a cikin ovaries amma ya ɓace yayin da mace ta kai kuma ta ci gaba ta hanyar menopause. A bayanin kula, yawancin cututtukan daji na ovarian suna faruwa bayan menopause, kuma AMHR2-ED an sake bayyana shi a yawancin ciwon daji na ovarian. Ta hanyar karbar maganin alurar riga kafi irin su Anixa's wanda ke kaiwa AMHR2-ED bayan ya kai ga al'ada, ciwon daji na ovarian, a tarihi daya daga cikin cututtukan cututtukan mata masu tsanani, za a iya hana shi daga tasowa.

Ayyukan da aka riga aka yi don ciyar da maganin rigakafin yana gudana ta hanyar Shirin PREVENT a Cibiyar Ciwon daji ta Kasa (NCI), wanda ke goyan bayan sababbin shirye-shirye na asali da kuma masu nazarin halittu don rigakafin ciwon daji da shiga tsakani. Bayanan preclinical da aka buga a cikin Binciken Rigakafin Ciwon daji a cikin 2017 yana goyan bayan ci gaba da ci gaba zuwa karatun asibiti.

Print Friendly, PDF & Email

Shafin Farko